文献速递胸部肿瘤

原发肺肿瘤立体定向体部放疗后联合同期纵隔放化疗及辅助免疫治疗用于局部晚期非小细胞肺癌:一项多中心、单臂、2期试验

Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2024-11-29

这项多中心单臂2期试验评估原发肺肿瘤SBRT后纵隔同步放化疗及辅助度伐利尤单抗治疗不可切除局部晚期NSCLC的疗效与安全性。61例患者中59例可评估,1年无进展生存率为62.7%(90%CI 51.2-73.2),未达到预设的60%阈值(单侧p=0.39)。治疗相关3-4级不良事件以中性粒细胞减少最常见(15%),治疗相关死亡4例(7%)。

要点

  • 原发灶SBRT后纵隔放化疗及辅助度伐利尤单抗的1年PFS为62.7%(90%CI 51.2-73.2),未达主要终点。
  • 治疗相关3-4级不良事件以中性粒细胞减少(15%)、白细胞减少(8%)和贫血(7%)最常见。
  • 治疗相关严重不良事件发生于11例(18%),治疗相关死亡4例(7%)。

核心结论

  • 尽管本研究未达到主要终点,原发肺肿瘤SBRT后联合同期纵隔放化疗的疗效和安全性特征与其他现代放化疗治疗局部晚期NSCLC的试验相比是有利的。
  • 这些发现为正在进行的随机3期研究NRG Oncology LU008(NCT05624996)提供了基础。

研究设计与样本

  • 多中心、单臂、2期试验,在美国北卡罗来纳州和南卡罗来纳州的8个区域癌症中心入组患者。
  • 入组标准为年龄18岁及以上、II-III期不可切除局部晚期NSCLC(任何组织学类型)、原发肿瘤≤7 cm(周围型或中央型,排除距受累淋巴结2 cm以内的中央型肿瘤)、ECOG体能状态0-2,排除既往接受过全身治疗或放疗者。
  • 治疗方案:原发肿瘤SBRT(50-54 Gy分3-5次),随后受累淋巴结标准放疗(计划至60 Gy分30次每次2 Gy)联合同期铂类双药化疗(紫杉醇50 mg/m2静脉注射+卡铂曲线下面积2 mg/mL每分,每7天一次共6个1周周期;或依托泊苷50 mg/m2静脉注射第1-5天和第29-33天+顺铂50 mg/m2静脉注射第1、8、29、36天,共2个4周周期)。
  • 2017年12月11日方案修订允许研究者酌情给予巩固度伐利尤单抗;2021年1月13日方案修订要求放化疗后无疾病进展者接受巩固度伐利尤单抗(10 mg/kg静脉注射每4周周期第1天和第15天,最多12周期;或1500 mg静脉注射每4周周期第1天,最多12周期)。
  • 主要终点为1年无进展生存率(依据RECIST 1.1),在至少接受1次SBRT分割且具有至1年影像学随访数据的全部参与者中评估;需1年无进展生存率大于60%以拒绝无效假设。安全性在至少接受1次SBRT分割的全部患者中评估。

主要发现

  • 2017年5月11日至2022年6月27日共入组61例患者并接受至少1次分割SBRT,其中59例可评估主要终点。
  • 中位年龄67岁(IQR 61-72);61例中女性28例(46%)、男性33例(54%);白人51例(84%)、黑人7例(11%)、其他或未知种族3例(5%)。
  • 61例入组患者中47例接受了至少1剂巩固度伐利尤单抗。
  • 截至数据截止日(2023年7月12日),中位随访29.5个月(IQR 14.9-47.1);1年无进展生存率为62.7%(90%CI 51.2-73.2;与历史对照率比较单侧p=0.39),59例可评估参与者中37例在入组后1年无进展且存活(14例进展,8例死亡)。
  • 最常见3-4级治疗相关不良事件为中性粒细胞计数降低(61例中9例[15%])、白细胞计数降低(5例[8%])和贫血(4例[7%]);治疗相关严重不良事件发生于61例中11例(18%),包括肺部感染(3例[5%])、肺炎(2例[3%])、中性粒细胞计数降低(2例[3%])、发热性中性粒细胞减少(2例[3%]),以及呼吸困难、低氧、呼吸衰竭、窦性心动过速、支气管感染和急性肾损伤(各1例[2%]);治疗相关死亡发生于61例中4例(7%)(呼吸衰竭、呼吸衰竭伴呼吸困难、肺部感染和肺炎各1例)。

局限性

  • 本研究未达到主要终点。
  • 这些发现为正在进行的随机3期研究NRG Oncology LU008(NCT05624996)提供了基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with locally advanced non-small-cell lung cancer (NSCLC) who undergo concurrent chemotherapy and radiotherapy often experience synergistic toxicity, and local regional control rates remain poor. We assessed the activity and safety outcomes of primary tumour stereotactic body radiotherapy (SBRT) followed by conventional chemoradiotherapy to the lymph nodes and consolidation immunotherapy in patients with unresectable locally advanced NSCLC. METHODS: In this multicentre, single-arm, phase 2 trial, patients aged 18 years and older were enrolled at eight regional cancer centres in North Carolina and South Carolina, USA. Patients were eligible if they had stage II-III, unresectable, locally advanced NSCLC (any histology), with peripheral or central primary tumours that were 7 cm or smaller, excluding central tumours within 2 cm of involved nodal disease, and an Eastern Cooperative Oncology Group performance status of 0-2. Patients who had previously received systemic therapy or radiotherapy were excluded. Participants received SBRT to the primary tumour (50-54 Gy in three to five fractions) followed by standard radiotherapy (planned up to 60 Gy in 30 2 Gy fractions) to the involved lymph nodes with concurrent platinum doublet chemotherapy (either paclitaxel 50 mg/m2 intravenously plus carboplatin area under the curve 2 mg/mL per min every 7 days for a total of six 1-week cycles or etoposide 50 mg/m2 intravenously on days 1-5 and days 29-33 plus cisplatin 50 mg/m2 intravenously on days 1, 8, 29, and 36 for two cycles of 4 weeks). An amendment to the protocol (Dec 11, 2017) permitted the administration of consolidation durvalumab at the discretion of the treating investigator. An additional protocol amendment on Jan 13, 2021, directed patients without disease progression after chemoradiotherapy to receive consolidation durvalumab (10 mg/kg intravenously on day 1 and day 15 of a 4-week cycle for up to 12 cycles or 1500 mg intravenously on day 1 of a 4-week cycle for up to 12 cycles). The primary endpoint was 1-year progression-free survival (per Response Evaluation Criteria in Solid Tumours version 1.1), assessed in all participants who received at least one fraction of SBRT and had radiological follow-up data up to 1 year. A 1-year progression-free survival rate of greater than 60% was required to reject the null hypothesis and show significant improvement in 1-year progression-free survival. One-sided exact binomial tests were used to compare the primary endpoint versus the historical control 1-year progression-free survival rate used to determine the sample size. Safety was assessed in all patients who received at least one fraction of SBRT. This study is registered with ClinicalTrials.gov, NCT03141359, and is closed to accrual. FINDINGS: Between May 11, 2017, and June 27, 2022, 61 patients were enrolled and received at least one dose of fractionated SBRT, of whom 59 were evaluable for the primary endpoint. Median age was 67 years (IQR 61-72), 28 (46%) of 61 were female, 33 (54%) were male, 51 (84%) were White, seven (11%) were Black, and three (5%) were of other or unknown race. Of the 61 patients enrolled, 47 received at least one dose of consolidation durvalumab. As of data cutoff (July 12, 2023), median follow-up was 29·5 months (IQR 14·9-47·1). 1-year progression-free survival was 62·7% (90% CI 51·2-73·2; one-sided p=0·39, compared with the historical control rate), with 37 of 59 evaluable participants progression free and alive 1 year after enrolment (n=14 progressed, n=8 died). The most common grade 3-4 treatment-related adverse events were decreased neutrophil count (nine [15%] of 61 patients), decreased white blood cell count (five [8%]), and anaemia (four [7%]). Treatment-related serious adverse events occurred in 11 (18%) of 61 patients, which included lung infection (three [5%]), pneumonitis (two [3%]), decreased neutrophil count (two [3%]), febrile neutropenia (two [3%]), and dyspnoea, hypoxia, respiratory failure, sinus tachycardia, bronchial infection, and acute kidney injury (each in one [2%] patient). Treatment-related deaths occurred in four (7%) of 61 patients (one each of respiratory failure, respiratory failure and dyspnoea, lung infection, and pneumonitis). INTERPRETATION: Although this study did not meet the primary endpoint, activity and safety profiles of primary lung tumour SBRT followed by concurrent mediastinal chemoradiotherapy were favourable compared with other modern trials treating locally advanced NSCLC with chemoradiotherapy. These findings serve as the basis for the ongoing randomised phase 3 study NRG Oncology LU008 (NCT05624996). FUNDING: AstraZeneca and Atrium Health Levine Cancer Institute.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Heinzerling JH, Mileham KF, Robinson MM, et al. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024. PMID: 39615497. doi:10.1016/S1470-2045(24)00573-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。